Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in the U.S.: $1,041M in FY2025, up 30.5% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
1,041
Period ended Dec 31, 2025
Change on a year earlier
+30.5%
798 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Ilaris | Immunology | Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) | 1 041 | 30 | 842 | 18 | 16 | 1 883 | 25 | 24”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in the U.S. ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,041 | +30.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 798 | +16.3% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 686 | +20.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 570 | +13.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 501 | +25.2% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 400 | +31.6% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 304 | +16.0% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2018 | Dec 31, 2018 | 262 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up net Sales in the U.S.
Cite this data
StockData. (2026). Novartis Net Sales in the U.S. ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-ilaris-us-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.